Stock Performance - Shares of Teva Pharmaceutical Industries lost 13.5% as of 1:15 p.m. ET, underperforming the S&P 500 and Nasdaq Composite, which lost 0.5% and 0.9%, respectively [1] Financial Results - Teva reported Q4 sales of $4.2 billion and fiscal year 2024 sales of $16.5 billion, up from 2023's revenue of $15.9 billion, slightly exceeding expectations [2] - Q4 EPS was $0.71, down significantly from Q4 2023's $1.00 but slightly exceeding the expected $0.70 [2] Guidance and Investor Sentiment - The company's 2025 EPS forecast disappointed investors, with the high end of the range ($2.65) coming in below the expected $2.76 [3] Strategic Initiatives - Teva is implementing its "Pivot to Growth strategy," focusing on cost reduction through reorganization, generics, and R&D pipeline success, though the latter has no guarantees or clear timeline [4] - The company has key drugs in later stages of trials, including treatments for ulcerative colitis and Crohn's disease, which show promise but require significant effort [5]

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday.The Dow traded down 0.16% to 44,778.55 while the NASDAQ fell 1% to 19,537.19. The S&P 500 also fell, dropping, 0.54% to 6,034.67.Check This Out: Jim Cramer: This Industrial Stock Is ‘Absolutely Terrific’, First Solar Is ‘Very Inexpensive’Leading and Lagging SectorsConsumer staples shares surged by 0.7% on Wednesday.In trading on Wednesday, information technology shares fell by 1.9%.Top HeadlineU.S. c ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric Hughes - Head of R&D & Chief Medical Officer Eli Kalif - CFO Conference Call Participants Umer Raffat - Evercore ISI Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Ash Verma - UBS Yifeng Liu - HSBC Glen Santangelo - Jefferies Chris Schulz - J.P. Morgan Operator Hello, a ...

Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.23 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 5.1%. EPS of $0.71 for the same period compares to $1.00 a year ago.The reported revenue represents a surprise of +3.13% over the Zacks Consensus Estimate of $4.1 billion. With the consensus EPS estimate being $0.70, the EPS surprise was +1.43%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street exp ...

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call January 29, 2025 08:00 AM ET Company Participants Christopher Stevo - SVP - Head of IRRichard Francis - President & CEOEric Hughes - Executive VP of Global R&D and Chief Medical OfficerEli Kalif - Chief Financial OfficerAshwani Verma - Executive DirectorGlen Santangelo - Managing DirectorChris Schott - Managing Director Conference Call Participants Umer Raffat - AnalystJason Gerberry - AnalystDavid Amsellem - Sr. Research AnalystBalaji Prasad - Ana ...

Non-GAAP Financial Measures This presentation includes certain non-GAAP financial measures as defined by SEC rules. Please see our press release reporting our financial results for 2024, as well as our Annual Report on Form 10-K for the year ended December 31, 2024, for a reconciliation of the non-GAAP financial measures to their nearest GAAP equivalents. Management believes that such non-GAAP financial measures provide useful information to investors to facilitate their understanding of our business becaus ...

EXHIBIT 99.1 Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth Q4 2024 and FY 2024 highlights: | | Q4 2024 | FY 2024 | | --- | --- | --- | | Revenues | $4.2 billion | $16.5 billion | | GAAP loss per share | $0.19 | $1.45 | | Non-GAAP diluted EPS | $0.71 | $2.49 | | | | $1,247 | | Cash flow generated from operating activities | $575 million | million | | | | $2,068 | | Free cash ...

Core Insights - Teva Pharmaceutical Industries Ltd. reported a transformative year in 2024, achieving a second consecutive year of growth driven by generic and innovative products [3][5] - The company generated revenues of $16.5 billion in FY 2024, reflecting a 6% increase in local currency terms compared to 2023 [5][8] - The company anticipates further progress in 2025, particularly in innovative growth drivers and complex generics [3][6] Financial Performance - Q4 2024 revenues were $4.2 billion, a decrease of 5% compared to Q4 2023 [26] - FY 2024 GAAP loss per share was $1.45, while non-GAAP diluted EPS was $2.49 [1][18] - Cash flow generated from operating activities in FY 2024 was $1.247 billion, down from $1.368 billion in 2023 [22][24] Product Performance - AUSTEDO revenues exceeded $1.6 billion, surpassing the 2024 outlook, while AJOVY generated $507 million, an 18% increase in local currency terms [5][8] - The generics business grew by 15% in the U.S. and 6% in Europe compared to 2023 [5][8] - Duvakitug (anti-TL1A) achieved positive Phase 2b results, with Phase 3 trials expected to initiate in 2025 [3][5] Strategic Initiatives - The "Pivot to Growth" strategy focuses on four key pillars: delivering growth engines, stepping up innovation, sustaining the generics business, and optimizing the portfolio [7][12] - The company is progressing with the sale of its active-pharmaceutical ingredient (API) business, which has been classified as held for sale [12][25] Segment Results - In the U.S. segment, revenues decreased by 13% to $1.975 billion in Q4 2024, primarily due to an upfront payment received in Q4 2023 [46][66] - The Europe segment reported revenues of $1.353 billion, a 1% increase compared to Q4 2023, with generic products driving growth [67][69] Research and Development - R&D expenses in FY 2024 were $998 million, a 5% increase compared to 2023, reflecting continued investment in innovative pipelines [11][30] - The company is advancing its late-stage innovative pipeline, particularly in immunology and neuroscience [11][12]

Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due out before the open Wednesday, Jan. 29. The stock snapped its positive post-earnings streak in November with a 7.1% loss, marking its first negative earnings reaction in six quarters. This time around, analysts expect the company to post earnings of 70 cents per share, and a 7.3% decrease in revenue from a year ago, per Reuters. On the charts, TEVA is still above its De ...

FDA Review and Biosimilar Development - The FDA has accepted Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi and Simponi Aria (golimumab), with the review process expected to be completed in Q4 2025 [1] - AVT05 is the first biosimilar candidate to golimumab to have its BLA filings accepted in the U S [1] - Alvotech's in-house capability to match the cell line and process used to manufacture the reference biologic has provided a significant advantage in developing AVT05 [2] Strategic Partnership and Commercialization - Alvotech and Teva Pharmaceuticals entered into a strategic partnership in August 2020 for the exclusive commercialization of five biosimilar product candidates, which has since expanded to include nine products [3] - Under the partnership, Alvotech handles development and manufacturing, while Teva is responsible for commercialization in the U S [3] - Two biosimilars developed under the partnership, SIMLANDI (adalimumab-ryvk) and SELARSDI (ustekinumab-aekn), have already received FDA approval [4] Clinical and Regulatory Progress - Alvotech announced positive top-line results from a confirmatory clinical study comparing AVT05 to Simponi in patients with moderate to severe rheumatoid arthritis in April 2024 [2] - A pharmacokinetic study comparing AVT05 to Simponi in healthy adults also showed positive results in November 2023 [2] - SIMLANDI, a biosimilar to Humira, was launched in the U S in May 2024, while SELARSDI, a biosimilar to Stelara, is planned for U S market entry in February 2025 [4] Product Pipeline and Market Reach - Alvotech's current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer [9] - The company has formed a network of strategic commercial partnerships to provide global reach, covering markets in the U S, Europe, Japan, China, and other regions [9] - SIMLANDI and SELARSDI are already approved and marketed in multiple global markets under various brand names [6][7] Industry Impact and Future Outlook - Biosimilars are becoming an integral part of the healthcare ecosystem, offering cost-saving options and better outcomes for patients with inflammatory conditions [2] - The strategic partnership between Alvotech and Teva underscores the commitment to expanding access to biosimilars and leveraging Teva's extensive sales and marketing infrastructure [3] - The FDA's acceptance of AVT05's BLA filings marks a significant step toward providing U S patients with access to biosimilar golimumab [1][2]